Perjeta
(Pertuzumab)Phase 3Monoclonal antibody
RochePertuzumab is used to treat certain types of breast cancer, particularly HER2-positive breast cancers. It works by blocking a protein that helps cancer cells grow and survive.[1] Perjeta is currently being investigated across 29 indications[3], with its most advanced program in Phase 3.[1]
Perjeta is one of 530 biologic programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.
29
Indications
230
Total Trials
77
Active Trials
529
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 29 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Perjeta
RochePhase 3
Trodelvy
GileadPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Avastin
RochePreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Fentanyl Citrate
IINSYS Therapeutics Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer143 trials
Show 140 more trials
Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04900311·490 enrolled
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Completed·—·Phase 2·NCT01847001·10 enrolled
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Completed·—·Phase 2·NCT02789657·32 enrolled
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Terminated·—·Phase 2·NCT01912963·32 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07377643·540 enrolled
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
Recruiting·—·Phase 2·NCT04993014·80 enrolled
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06278870·312 enrolled
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Not yet recruiting·—·Phase 2·NCT05983094·181 enrolled
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04337658·493 enrolled
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04760431·120 enrolled
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07246317·188 enrolled
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07340398·200 enrolled
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04398914·216 enrolled
A Study for the Neoadjuvant Treatment of Breast Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420454·1,576 enrolled
A Study for the Adjuvant Treatment of Breast Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420467·2,413 enrolled
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Recruiting·—·Phase 2·NCT06439693·72 enrolled
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05159193·372 enrolled
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04717531·60 enrolled
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
Active, not recruiting·—·Phase 2·NCT02827877·18 enrolled
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Unknown status·—·Phase 2·NCT04197687·480 enrolled
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
Active, not recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07421141·186 enrolled
Neoadjuvant Treatment4 trials
Metastatic Colorectal Cancer3 trials
Ovarian Cancer3 trials
Non-Small Cell Lung Cancer3 trials
35 more indications
Neoadjuvant2 trials
Advanced Solid Tumors2 trials
Immunotherapy2 trials
Immunogenicity2 trials
Paclitaxel2 trials
Patients With Advanced Solid Tumors2 trials
Gastric Cancer2 trials
Esophageal Carcinoma1 trial
Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Completed·—·Phase 1/2·NCT02120911·40 enrolled
Fallopian Tube Cancer1 trial
Ptosis1 trial
Phase II1 trial
Neuroendocrine Cancer1 trial
Cancer1 trial
Advanced/Metastatic Solid Tumors1 trial
Esophageal Cancer1 trial
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Recruiting·—·Phase 3·NCT05188313·376 enrolled
Trial1 trial
Left Ventricular Dysfunction1 trial
Patients With Solid Tumors1 trial
Pancreatic Adenocarcinoma1 trial
Dendritic Cell1 trial
Neuroendocrine Tumors1 trial
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Terminated·—·Phase 2·NCT00947167·4 enrolled
Carboplatin1 trial
HER2 Positive1 trial
HER21 trial
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Active, not recruiting·—·Phase 2·NCT02326974·164 enrolled
Vaccine1 trial
Colorectal Cancer1 trial
Unspecified3 trials
MARGetuximab Or Trastuzumab (MARGOT)
Active, not recruiting·—·Phase 2·NCT04425018·174 enrolled
Regulatory
FDA Approval Timeline[4]
Jun 8, 2012
PERJETA
BLA BLA125409
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pertuzumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]